title: Bioequivalence study of a film-coated tablet of deferiprone in healthy Thai volunteers.
abstract: OBJECTIVE
  To evaluate the bioequivalence of a single dose of deferiprone tablet manufactured locally (GPO-L-ONE, GPO, Thailand) with a reference formulation (Ferriprox, ApoPharma, Canada).
  
  
  METHODS
  A randomized, single dose, two-treatment, two-period, two- sequence crossover study was conducted in 24 healthy volunteers. Each subject received a single dose of 3 tablets of 500 mg deferiprone of both formulations with a two-week washout period. Blood samples were collected at 12 points for 480 min. Serum deferiprone levels were analyzed using high performance liquid chromatography (HPLC) method. Pharmacokinetic parameters were calculated from serum concentration-time curve and applying the non-compartment model. Statistical comparisons of Cmax, AUC(0-t), AUC(0-inf) values were evaluated after logarithmic transformation. Other pharmacokinetic parameters were tested non-parametrically.
  
  
  RESULTS
  The C(max) value (mean +/- SD) for reference and test product was 32.4 +/- 13.2 and 27.8 +/- 12.8 microg/ml, respectively. Mean ratio (test/reference) of C(max) was 0.852 with 90% CI of 0.772 - 0.934. Mean ratio (test/reference) of AUC(0-t) was 0.962 with 90% CI of 0.914 to 1.012, and of AUC(0-inf) was 0.966 with 90% CI of 0.918-1.016. Both formulations were well tolerated and no adverse effects were observed.
  
  
  CONCLUSIONS
  The 90% CI of mean ratio of AUC(0-t) and AUC(0-inf) fell within the acceptable range (0.80 - 1.25) for bioequivalent eligibility. Regarding the efficacy of deferiprone, which depends on AUC rather than C(max), 90% CI of mean ratio of C(max) was within the acceptable range of WHO criteria for bioequivalence study (0.75 - 1.33). Therefore the two film-coated formulations of deferiprone tablet were proven bioequivalent in healthy Thai volunteers.
authors.affiliation: Department of Pharmacology, Faculty of Science, Mahidol University, Rajatevee, Bangkok, Thailand. scnpm@mahidol.ac.th
authors.forename: N P
authors.initials: NP
authors.lastname: Morales
authors.lastname: L
authors.forename: P
authors.initials: P
authors.lastname: Yamanont
authors.forename: T
authors.initials: T
authors.lastname: Jirasomprasert
authors.forename: P
authors.initials: P
authors.lastname: Wilairat
authors.forename: U
authors.initials: U
authors.lastname: Chantharaksri
authors.forename: S
authors.initials: S
authors.lastname: Chuncharunee
authors.forename: S
authors.initials: S
authors.lastname: Fucharoen
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D019540:Area Under Curve; D002851:Chromatography, High Pressure Liquid; D018592:Cross-Over Studies; D000077543:Deferiprone; D005260:Female; D006801:Humans; D007502:Iron Chelating Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D008297:Male; D008875:Middle Aged; D011728:Pyridones / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D013607:Tablets; D013785:Thailand; D013810:Therapeutic Equivalency; D055815:Young Adult
chemical_list: D007502:Iron Chelating Agents; D011728:Pyridones; D013607:Tablets; D000077543:Deferiprone